These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Novel challenges associated with novel agents: the evolving scenario in renal cell carcinoma. Di Lorenzo G; Buonerba C Future Oncol; 2016 Feb; 12(3):277-9. PubMed ID: 26768297 [No Abstract] [Full Text] [Related]
30. Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients. Rubio-Viqueira B; Hidalgo M Clin Pharmacol Ther; 2009 Feb; 85(2):217-21. PubMed ID: 19005462 [No Abstract] [Full Text] [Related]
31. Response biomarkers: re-envisioning the approach to tailoring drug therapy for cancer. Amin S; Bathe OF BMC Cancer; 2016 Nov; 16(1):850. PubMed ID: 27814715 [TBL] [Abstract][Full Text] [Related]
32. [Targeted therapy: old and new possibilities]. Hochhaus A; Lüftner D; Mackensen A Onkologie; 2013; 36 Suppl 5():2-11. PubMed ID: 23921800 [No Abstract] [Full Text] [Related]
33. Targeted therapy in cancer. Tsimberidou AM Cancer Chemother Pharmacol; 2015 Dec; 76(6):1113-32. PubMed ID: 26391154 [TBL] [Abstract][Full Text] [Related]
34. RB1 dual role in proliferation and apoptosis: cell fate control and implications for cancer therapy. Indovina P; Pentimalli F; Casini N; Vocca I; Giordano A Oncotarget; 2015 Jul; 6(20):17873-90. PubMed ID: 26160835 [TBL] [Abstract][Full Text] [Related]
35. Few positives for triple-negative breast cancer. Hede K J Natl Cancer Inst; 2011 Apr; 103(7):532-3. PubMed ID: 21436063 [No Abstract] [Full Text] [Related]
36. The search for optimal response prediction in cancer leads to a personalized approach. Van Cutsem E; Ciardiello F Target Oncol; 2010 Mar; 5(1):3-4. PubMed ID: 20349283 [No Abstract] [Full Text] [Related]
37. Criticism of tumor response criteria raises trial design questions. Twombly R J Natl Cancer Inst; 2006 Feb; 98(4):232-4. PubMed ID: 16478740 [No Abstract] [Full Text] [Related]